SQLE promotes osteosarcoma progression via activating TGFβ/SMAD signaling pathway

Qi Song1, Lina He1, Jing Feng1

  • 1Department of Trauma Surgery, Wuhan No. 1 Hospital, Wuhan, 430022, Hubei Province, China.

PubMed
Abstract

Insights

Squalene epoxidase (SQLE) is upregulated in osteosarcoma (OS), promoting tumor growth and metastasis. Targeting SQLE may offer a new therapeutic strategy for OS patients, improving prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma (OS) prognosis remains poor, necessitating novel therapeutic targets.
  • Squalene epoxidase (SQLE), key in cholesterol metabolism, is implicated in cancer, but its role in OS is unclear.

Purpose of the Study:

  • To investigate the role of SQLE in OS progression.
  • To explore the underlying mechanisms of SQLE action in OS.

Main Methods:

  • Compared SQLE expression in OS and normal tissues via bioinformatics and experiments.
  • Conducted survival analysis and Cox regression for prognostic value.
  • Utilized loss- and gain-of-function studies on OS cell lines.
  • Investigated SQLE's effect on TGFβ/SMAD signaling pathway.

Main Results:

  • SQLE expression is significantly elevated in OS tissues and cell lines.
  • High SQLE expression correlates with poorer patient survival and acts as an independent prognostic biomarker.
  • SQLE knockdown inhibits OS cell proliferation, migration, and invasion; overexpression enhances these.
  • SQLE activates the TGFβ/SMAD signaling pathway in OS.

Conclusions:

  • SQLE acts as a tumor-promoting factor and prognostic predictor in OS.
  • SQLE drives OS progression by activating TGFβ/SMAD signaling.
  • Targeting SQLE presents a potential therapeutic strategy for osteosarcoma.